Home › Gliosarcoma
Gliosarcoma clinical trials recruiting in the U.S.
9 studies for Gliosarcoma are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07301268MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07089641A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 14, 2026 · NCT05698524Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06934889Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT04991870HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 4, 2026 · NCT05756985Study of Pembrolizumab and M032 (NSC 733972)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 22, 2026 · NCT05084430From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.